FREE MEMBERSHIP Includes » ABL Advisor eNews + iData Blasts | JOIN NOW ABLAdvisor Gray ABLAdvisor Blue
Skip Navigation LinksHome / News / Read News


Diadexus to File Chapter 7 as Oxford Accelerates Debt Repayment

June 13, 2016, 12:22 PM
Filed Under: Medical

Diadexus, Inc., a diagnostics company developing and commercializing products that aid in assessing the prognosis of cardiac disease, announced that it is filing for relief under Chapter 7 of Title 11 of the U.S. Bankruptcy Code in order to initiate an orderly liquidation of the assets of the company. The company has been notified that its lender, Oxford Finance LLC, exercised certain of its rights under the August 2014 Loan and Security Agreement, including with respect to acceleration of obligations and demand for repayment and the removal of all of the available cash and investments from the accounts of the company.

The Chapter 7 case will be filed in the U.S. Bankruptcy Court for Northern District of California. Upon the filing, a Chapter 7 trustee will be appointed in the case and the assets of the company will be liquidated in accordance with the bankruptcy code. Additional information on the process may be obtained through the bankruptcy court.

The company has been in discussions with Oxford Finance LLC for several months in an attempt to restructure its current loan agreement and reduce near-term financial constraints on its business but has been unable to reach an agreement. As of March 31, 2016, $13.3 million in principal remained outstanding under the Loan and Security Agreement with Oxford. As part of this process, the company engaged Alvarez & Marsal Healthcare Industry Group, LLC as its restructuring advisor.

The company also announced that Leone Patterson, the Company's Chief Financial Officer (CFO) since March 2015, has notified Diadexus that she will be leaving effective immediately.

Diadexus, based in South San Francisco, CA, is a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, providing healthcare providers with actionable information for managing patients. The Company pioneered the testing of Lp-PLA2, a marker of vascular-specific inflammation that provides new information, over and above traditional risk factors measured in a lipid panel, and has over a decade of peer-reviewed literature validating its utility. Diadexus' products, the PLAC® Test ELISA Kit, first cleared by the FDA in 2003, and the PLAC® Test for Lp-PLA2 Activity, cleared in December 2014, are the only two FDA-cleared tests to measure Lp-PLA2.

Week's News

Comments From Our Members

You must be an ABL Advisor member to post comments. Login or Join Now.